Kinetics of neutralising antibodies against Omicron variant in Vietnamese healthcare workers after primary immunisation with ChAdOx1-S and booster with BNT162b2

We studied the development and persistence of neutralising antibodies against SARS-CoV-2 ancestral strain, and Delta and Omicron (BA.1 and BA.2) variants in Vietnamese healthcare workers (HCWs) up to 15 weeks after booster vaccination. We included 47 HCWs with different pre-existing immune statuses (group 1 (G1): n=21, and group 2 (G2): n=26 without and with prior breakthrough Delta variant infection, respectively). The study participants had completed primary immunisation with ChAdOx1-S and booster vaccination with BNT162b2. Neutralising antibodies were measured using a surrogate virus neutralisation assay. Of the 21 study participants in G1, neutralising antibodies against ancestral strain, Delta variant, BA.1 and BA.2 were (almost) abolished at month 8 after the second dose, but all had detectable neutralising antibodies to the study viruses at week two post booster dose. Of the 26 study participants in G2, neutralising antibody levels to BA.1 and BA.2 were significantly higher than those to the corresponding viruses measured at week 2 post breakthrough infection and before the booster dose. At week 15 post booster vaccination, neutralising antibodies to BA.1 and BA.2 dropped significantly, with more profound changes observed in those without breakthrough Delta variant infection. Booster vaccination enhanced neutralising activities against ancestral strain and Delta variant, as compared to those induced by primary vaccination. These responses were maintained at high levels for at least 15 weeks. Our findings emphasise the importance of the first booster dose in producing cross-neutralising antibodies against Omicron variant. A second booster dose might be needed to maintain long-term protection against Omicron variant.

CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. ; The Wilcoxon signed-rank test or the paired T-test was used to compare the differences 1 1 2 in neutralizing antibody levels to ancestral strain, Delta, BA.1 and BA.2 between and 1 1 3 within groups when appropriate. The Spearman's correlation was used to assess the 1 1 4 correlation of neutralizing antibody levels and age. All analyses were performed using 1 1 5 GraphPad Prism 9.3.1 (GraphPad Software, La Jolla, CA, USA). The study received approvals from the Institutional Review Board of the Hospital for Ethics Committee. Written informed consent was obtained from all the study participants. During the follow up, 9 individuals, including 5/21 (24%) participants of G1 and 4/26 1 2 7 (15%) participants of G2, had a SARS-CoV-2 infection episode recorded after the 1 2 8 booster dose (Figure 1). Although detailed clinical descriptions were not available, no 1 2 9 hospitalisation was reported, suggesting that all were either asymptomatic or mildly . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 21, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022 sampling at month three after booster vaccination was 28 (range: 12-103) for G1 and 17 1 3 4 (range: 8-22) for G2. Of the 21 participants in G1, at week two after the primary course, detectable neutralising 1 3 8 antibodies against ancestral strain and Delta variant were documented in 21 (100%) and  limit of the sVNT assay ( Figure 2A and Table 2). Of the 21 participants in G1, before the booster dose (i.e. month 8 after dose 2), none had and Delta variant were 8/21 (38%) and 2/21 (10%), respectively, with neutralising titers 1 4 9 approaching the assay detection limit (Figure 2A). At week 2 after the booster dose, all  Notably neutralising antibody levels to ancestral strain, and Delta variant measured at 2 1 5 2 weeks after the booster dose were significantly higher than those to the respective viruses . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

5 8
Of the 26 participants in G2, neutralising antibodies against ancestral strain, Delta, BA.1 1 5 9 and BA.2 measured at week 2 after breakthrough infection were detectable in 24 (92%), BA.2 ( Figure 2B and Table 2). At week 2 after booster vaccination, neutralising antibody 1 6 3 levels to BA.1 and BA.2 significantly increased as compared to those measured before 1 6 4 the booster dose and at 2 weeks post breakthrough infection, but remained significantly 1 6 5 lower than those against ancestral strain and Delta variant ( Figure 2B and Table 2). At To assess the persistence of neutralising antibodies induced by the booster dose, we first . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. ; https://doi.org/10.1101/2022.06.20.22276596 doi: medRxiv preprint (90.4-95.7), p=0.034) ( Figure 3A). Neutralising antibodies against Delta variant also 1 7 9 slightly reduced, but remained at very high titers ( Figure 3A).  Results of linear regression analysis showed no association between age and neutralizing considered uninformative because neutralising antibody levels to these two viruses in all 1 9 5 study participants reached the upper detection limit of the assay (100%) (Figure 3). We showed that neutralising antibodies induced by primary immunization with  Heterologous booster vaccination with BNT162b2 improved the immunity that could Delta variant remained at high titers. We found no association between age and 2 0 6 neutralising antibody levels, in line with a recent report [12], but none of our study 2 0 7 participants were older than 57 years. Our findings are consistent with existing data    week 15 after the first booster dose suggest that a second booster doses might be needed . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. BNT162b2 vaccine was effective in reducing the risk of COVID-19 associated outcomes  Our study consistently showed that neutralising antibody tiers against BA.2 after the  BA.2 is less able to evade immunity than BA.1 merits further research.

4 0
Our study has several limitations. First, we did not perform live virus neutralisation 2 4 1 assay, currently the gold standard, to measure neutralising antibodies. However, the 2 4 2 percentage of inhibition measured by the sVNT test has been shown to correlate well 2 4 3 with the neutralizing antibody titers measured by the conventional plaque reduction 2 4 4 neutralization assay [19]. Second, we did not study T-cell responses, which have been 2 4 5 proven to play an important role in protecting against severe disease and death, and in 2 4 6 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

7.
Stockholm, E., European Centre for Disease Prevention and Control.
3 1 5   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022   is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted June 21, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 21, 2022. ; https://doi.org/10. 1101/2022